Skip to main content Skip to footer
Algernon Pharmaceuticals Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Apr 29, 2020 8:30am EDT

Algernon Presents “The Science of Ifenprodil” on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD

Apr 23, 2020 7:30am EDT

Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea

Apr 22, 2020 7:30am EDT

Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

Apr 15, 2020 8:30am EDT

Algernon Receives Positive Feedback from U.S. FDA for New Ifenprodil Intravenous Formulation

Apr 13, 2020 11:34am EDT

Algernon CEO and CSO to be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Apr 13, 2020 8:30am EDT

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board

Apr 09, 2020 8:30am EDT

Algernon Announces Regulatory Submission for Ifenprodil COVID-19 Human Trial in South Korea

Apr 08, 2020 8:30am EDT

Algernon Announces Positive Feedback from Health Canada for Ifenprodil COVID-19 Phase 2 Human Trial

Apr 02, 2020 8:30am EDT

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19

Mar 30, 2020 8:30am EDT

Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2025 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap